Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash from Financing Activities (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Cash from Financing Activities for 5 consecutive years, with -$6.7 million as the latest value for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 14370.21% year-over-year to -$6.7 million; the TTM value through Dec 2025 reached -$10.6 million, down 10376.7%, while the annual FY2025 figure was -$10.6 million, 10376.7% down from the prior year.
  • Cash from Financing Activities hit -$6.7 million in Q4 2025 for Kezar Life Sciences, down from -$1.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $99.4 million in Q4 2021 and bottomed at -$6.7 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $12.8 million, with a median of $169500.0 recorded in 2022.
  • Year-over-year, Cash from Financing Activities skyrocketed 27673.76% in 2022 and then tumbled 14370.21% in 2025.
  • Kezar Life Sciences' Cash from Financing Activities stood at $99.4 million in 2021, then crashed by 99.49% to $506000.0 in 2022, then plummeted by 88.34% to $59000.0 in 2023, then fell by 20.34% to $47000.0 in 2024, then crashed by 14370.21% to -$6.7 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$6.7 million, -$1.3 million, and -$1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.